MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above

AstraZeneca's earnings slump as revenues slide

AstraZeneca said Thursday third-quarter earnings fell by more than a third as a slump in externalisation revenue, lower margins and increased costs weighed on performance.

For the three months to 30 September, revenue fell 14% to $5.34bn and earnings per share fell 37% to $0.71 a share in the third quarter of the year.

The fall in revenue was exacerbated by a decline in externalisation revenue, an income raising measure which includes money raised from selling assets or collaborating with other companies to develop drugs.

Externalisation revenue fell 81% to $392m as AztraZeneca's collaboration with MSD on their Lynparza treatment weighed.

Product sales increased by 8% in third quarter to $5.27bn driven by the performance of newer cancer drugs as oncology saw sales growth of 30% during the quarter.

For the nine months to September 30, pre-tax profit fell 31% to $1.26bn from $1.820m a year earlier.

AstraZeneca reiterated its outlook for core earnings per share of $3.30 to $3.50, and full-year product sales are expected to increase in low single-digit percentage, at constant currency rates.

Story provided by